bictegravir

01/01/2019 - "Here, we tested FDA-approved and two Phase II HIV-1 INSTIs in vitro and in a cell-to-cell infection model and show that they are highly active in blocking HTLV-1 infection, with bictegravir (EC50 = 0.30 ± 0.17 nM) performing best overall. "
12/01/2022 - "Human pharmacokinetics prediction with an in vitro-in vivo correction factor approach and in vitro drug-drug interaction profile of bictegravir, a potent integrase-strand transfer inhibitor component in approved biktarvy® for the treatment of HIV-1 infection."
11/18/2022 - "The high IIP values of bictegravir and BSS-730A for raltegravir-naïve and raltegravir-resistant HIV-2 isolates highlight their potential value for treating HIV-2 infection. "
09/01/2022 - "Human and nonclinical disposition of [14C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infection."
11/01/2021 - "Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection."

01/01/2022 - "Since bictegravir is also an INSTI, it is expected to show a similar weight gain. "
10/22/2022 - "The long-term clinical implications of weight gain associated with second generation INSTIs dolutegravir and bictegravir warrants further study. "
01/01/2023 - "Overall, H/DM was associated with bictegravir and dolutegravir and weight gain with all INSTIs. "
02/08/2022 - "Within the INSTI class, dolutegravir and bictegravir appear to have the greatest propensity for weight gain. "
01/01/2022 - "The therapy was then switched to an equally potent integrase strand inhibitor bictegravir to get the benefit of efficacy of antiretroviral therapy and avoid the weight gain effect seen with DTG. "

01/01/2020 - "Total and Unbound Bictegravir Concentrations and Viral Suppression in Cerebrospinal Fluid of Human Immunodeficiency Virus-Infected Patients (Spanish HIV/AIDS Research Network, PreEC/RIS 56)."
10/05/2021 - "Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58)."
06/11/2020 - "In a separate development, HIV integrase strand transfer inhibitors (INSTIs) have shown efficacy in treating AIDS, including raltegravir (RAL), elvitegravir (EVG), cabotegravir (CAB), bictegravir (BIC), and dolutegravir (DTG). "

11/01/2023 - "Ocular syphilis diagnosis was posed after initial misdiagnosing with cytomegalovirus infection, and antiretroviral therapy compliance improved after switching to a bictegravir-based regimen. "

11/01/2021 - "In this article, we illustrate a case of an HIV+ patient whose psoriasis drastically improved after the initiation of highly active antiretroviral therapy (HAART) consisting of bictegravir, emtricitabine, and tenofovir alafenamide. "